Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS and inhibit the degradation of endocannabinoids in order to improve uptake of THC.
Product Name : SCI-110
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 15, 2023
Lead Product(s) : Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable